SYRS News and Press, Syros Pharmaceuticals Inc. From 03/04/21

Syros Pharmaceuticals (SYRS): Q4 GAAP EPS of -$0.62 misses by $0.12.Revenue of $5.7M (+1017.6% Y/Y) beats by $3.01M.Press Release For further details see: Syros Pharmaceuticals EPS misses by $0.12, beats on revenue

Initiated Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients On Track to Initiate Two Additional Clinical Trials Across Hematology Franchise in 2H 2021 On Track to Report Additional Dose-Escalation Data fo...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 4, 2021 to report its fourth quarter and full year 2020 financial r...

Syros Pharmaceuticals (SYRS) has priced its public offering of 5.4M common shares at $14.00/share, which would result in gross proceeds of ~$75.6M.Underwriters' over-allotment is an additional 810K shares.The proceeds are expected to be used for the development of ongoing clinical and preclin...

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per share, which would result ...

Gainers: [[PCTI]] +20.5%. [[GRTS]] +19.1%. [[NFLX]] +11.9%. [[CLFD]] +11.8%. [[BRMK]] +7.5%.Losers: [[ACRX]] -12.8%. [[PERI]] -8.3%. [[LAC]] -8.3%. [[DSS]] -8.2%. [[SYRS]] -7.7%. For further details see: PCTI, NFLX, ACRX and DSS among after-hours movers

Syros Pharmaceuticals (SYRS) offers to sell shares in an underwritten public offering; underwriters granted 30-day option to purchase additional 15% shares.Proceeds to be used for funding the development of Syros' ongoing clinical and preclinical programs, and for general corporate purposes.A...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell shares of its common stock in an underwritten public offering. The proceeds of the offering are expected to be used to fund the...

Conference date in details should read: Thursday, January 14 (instead of Thursday, January 7) The updated release reads: SYROS TO PRESENT AT 39 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines t...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the virtual 39 th Annual J.P. Morgan Healthcare Conference...